מזומנים למניה אחת Genelux (GNLX)

The cash per share chart illustrates the liquidity of Genelux Corporation (GNLX), where the indicator value reaches 0.22. A lack of sales due to the testing stage deprives the company of pricing power. The business relies on patent protection for oncolytic platforms and partnerships with pharmaceutical behemoths. Market capitalization growth is expected following third-phase trial data and demand for tumor immunotherapy.
פילוחים אנליטיים של חברת Genelux Corporation

As a biotechnology startup in the clinical trial stage with no proprietary sales, Genelux Corporation (GNLX) is critically dependent on external financing. The company's cash per share trend reflects the volume of liquid reserves available to sustain operations, allowing investors to assess the business's financial runway and the risk of default before products reach the market.